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Abstract: Refractory angina is a debilitating disease characterized by persistent cardiac 
pain resistant to all conventional treatments for coronary artery disease. Percutaneous myo-
cardial laser revascularization (PMLR) has been proposed to improve symptoms in these 
patients. We used meta-analysis to assess the effectiveness of PMLR versus optimal medical 
therapy for improving angina symptoms, health-related quality of life (HRQL), and exercise 
performance; the impact on all-cause mortality was also examined. Seven trials, involving 
a total of 1,213 participants were included. Our primary analyses showed that at 12-month 
follow-up, those who had received PMLR had $2 Canadian Cardiovascular Society class 
angina symptom reductions, OR 2.13 (95% CI, 1.22 to 3.73), as well as improvements in 
aspects of HRQL including angina frequency, SMD = 0.29 (95% CI, 0.05 to 0.52), disease 
perception, SMD = 0.37 (95% CI, 0.14 to 0.61), and physical limitations, SMD = 0.29 (95% 
CI, 0.05 to 0.53). PMLR had no significant impact on all-cause mortality. Our secondary 
analyses, in which we considered data from one trial that featured a higher-dose laser group, 
yielded no significant overall impact of PMLR across outcomes. While PMLR may be effec-
tive for improving angina symptoms and related burden, further work is needed to clarify 
appropriate dose and impact on disease-specific mortality and adverse cardiac events.
Keywords: refractory angina, percutaneous laser revascularization, angina symptoms, 
  health-related quality of life, meta-analysis
Introduction
Refractory angina (RFA) is a debilitating disease characterized by persistent cardiac 
pain.1–3 This pain/discomfort, by definition, is resistant to all conventional treatments for 
coronary artery disease (CAD) including nitrates, calcium-channel and β   adrenoceptor 
blockade, vasculoprotective agents, percutaneous coronary interventions, and coronary 
artery bypass grafting.1–3 Patients living with RFA have a low annual mortality rate of 
3% but suffer severely impaired health-related quality of life (HRQL).4 They typically 
experience recurrent and sustained pain, poor general health status, psychological distress, 
impaired role functioning, activity restriction, and inability to self-manage.5–8 The global 
prevalence of RFA is increasing, likely due to improvements in revascularization techniques 
and patients’ increased survival after primary and subsequent cardiac events.1,2,9,10
Percutaneous myocardial laser revascularization (PMLR) therapy emerged as 
a treatment option for RFA in the 1990s, as an alternative to transmyocardial laser 
  revascularization (TMLR). A major impetus for adopting PMLR, across several 
  countries, was the elimination of the incumbent risks of sternotomy and/or left anterior 
thoracotomy required for the TMLR procedure.11–13 PMLR entails the application of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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holmium: yttrium aluminum garnet (holmium: YAG) laser 
energy to the endocardial surface of the left ventricle via a 
flexible catheter; laser firing is   synchronized during systole to 
create a series of   nontransmural channels in targeted regions 
with reversible ischemia.11,12 As with TMLR,14 the mecha-
nisms of action during PMLR are unclear. Proposed laser 
mechanisms with insufficient and/or contradictory evidence 
include direct perfusion,15–18 microvascular angiogenesis,19–23 
and cardiac afferent denervation.24–27 There is also insufficient 
evidence to support placebo effect13,28 and change in attitudes 
and expectations24 towards angina as significant factors in 
symptom relief.
While the mechanisms of therapeutic benefit have remained 
in question, symptom relief, improvements in exercise duration, 
HRQL, and safety have been reported in several randomized 
controlled trials (RCTs).12,13,29,30–32 For example, Salem et al31 
found sustained angina relief, without revascularization, up 
to 3 years post-intervention in the absence of procedural 
mortality, myocardial   infarction (MI), or cerebral embolism; 
cardiac event-free survival (cardiac death, MI, stroke, transient 
ischemic attack,   myocardial perforation, rehospitalisation) was 
88% at one year and 66% at late follow-up (mean = 3 years).31 
Despite some positive   findings, PMLR has since fallen out of 
favor in a number of centers due to ongoing controversy over 
mechanisms and effectiveness. Effective treatment options for 
RFA symptoms are, however, limited, and reviews of PMLR 
trial data to date have been narrative-based. A 2009 Cochrane 
Review clearly demonstrated that the observed clinical benefits 
of TMLR do not outweigh the potential perioperative risks.14 
Given that PMLR is a less invasive approach, we felt that the 
available data on clinically relevant patient outcomes should 
be subjected to a level of meta-analytic rigor comparable to 
that of TMLR in order to offer more definitive conclusions 
about its effectiveness for symptom relief.
Objectives
This review aims to determine the effectiveness of PMLR 
plus maximal medical therapy (MMT) versus MMT alone for 
improving pain symptoms, HRQL, and exercise performance 
in patients with RFA. All-cause mortality was examined as 
a secondary outcome.
Criteria for selection of studies 
included in this review
Study designs
All published and unpublished RCTs of PMLR with parallel 
designs; follow-up period varied. Nonrandomized studies and 
single-group design studies were excluded.
Participants
Adult RFA patients 18 years or older with CAD determined 
angiographically or via nuclear imaging, class III or IV 
angina according to the Canadian Cardiovascular Society 
(CCS) angina classification scale, and maximally-tolerated 
doses of antianginal therapy, most typically including 
  beta-blockers, calcium antagonists, and nitrates. Those 
patients included were also no longer eligible for conventional 
revascularization procedures including coronary artery bypass 
grafting (CABG) and percutaneous coronary intervention 
(PCI) due to a) unsuitable coronary anatomy such as diffuse 
sclerosis and lesions not amenable to intervention (eg, unpro-
tected left main, distal, or highly calcified), or b) extracardiac 
diseases resulting in unacceptable perioperative risk including 
(but not limited to) carotid stenosis, renal insufficiency, and 
chronic obstructive pulmonary disease (COPD).
Types of interventions and controls
PMLR performed via percutaneous arterial access using a 
holmium: YAG laser system was compared with maximally-
tolerated antianginal therapy. Studies included patients who 
may have undergone conventional revascularization   procedures 
(CABG or PCI) prior to the study period. Studies that included 
additional therapies as adjuvants to PMLR, such as intramyo-
cardial autologous bone marrow cell implantation and vascular 
endothelial growth factor implantation, were excluded.
Outcomes
1.  Angina symptoms
2.  Self-reported HRQL via generic or disease-specific 
instruments
3.  Exercise duration
4.  All-cause mortality
Search methods for identification  
of studies
We searched the Cochrane Central Register of Controlled 
Trials, MEDLINE, PubMed, CINHAL, EMBASE,   Proquest 
Dissertation Abstracts, Psychinfo, and HealthStar, from Jan 
1999–June 2009, using combinations of key   medical subject 
heading (MeSH) terms including refractory angina, stable 
angina, angina pectoris, laser therapy, laser revascularization, 
percutaneous laser   revascularization, Holmium:YAG laser, 
randomized controlled trials, and clinical trials. We also 
conducted hand searches of   relevant journals,   proceedings 
of major conferences, and   secondary references; experts in 
the field were consulted for   additional sources. Our search 
  strategy was critiqued and replicated by an external 
  information specialist to ensure comprehensiveness.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Methods
Final selection of trials
Five reviewers reached consensus on all trials to be included 
in this meta-analysis by reviewing the titles, abstracts, and 
reports of all trials according to the inclusion criteria specified 
a priori; individual trial results were not considered during 
this process.
Data extraction and appraisal  
of methodological quality
Four reviewers participated in independent quality assessment 
and extraction of process and outcome data from each trial 
according to a data extraction form developed for this review. 
The methodological quality of included trials was appraised 
via standard Cochrane criteria for risk of bias assessment33 
including generation of randomization sequence; alloca-
tion concealment; blinding of participants, personnel, and 
outcome assessors (detection bias); use of sham procedure 
  (placebo effect); standardized intervention delivery and 
presence of cointervention (performance bias); reliability 
and validity of measurement instruments (insensitive mea-
surement bias); response rate (RR) and attrition (attrition 
bias); and selective reporting (reporting bias). Propensity 
for selection bias was also assessed. Reported outcome data 
were taken directly from included published reports, and 
consensus among the four reviewers was reached across trials 
on quality assessment and data extracted.
Data synthesis and analysis
Continuous outcomes were summarized using standardized 
mean differences (SMD). These were determined using 
differences in change over baseline at the end of treatment, 
across treatment groups, divided by the pooled standard devi-
ation. If change over baseline was unavailable, differences in 
mean values at the end of treatment were used. For studies 
reporting only medians and interquartile ranges (IQR) for 
continuous outcomes, we planned to estimate means and 
standard deviations (SD) using the method outlined by Hozo 
et al34 Tomlinson and Beyene35 have suggested that omis-
sion of studies reporting only medians and IQRs may lead 
to a loss of important information. A SMD of 0.20 standard 
deviation units was considered a small difference between 
the experimental and control groups, a SMD of 0.50 a 
moderate difference, and 0.80 a large difference.36,37 Binary 
outcomes were expressed as odds ratios. We used standard 
inverse-variance   random-effects   meta-analysis to combine 
the trials.38 Heterogeneity between trials was evaluated 
using Chi-squared tests for the Tau-squared statistic and 
quantified using the I2 statistic,39 which describes the 
percentage of variation across trials that is attributable to 
heterogeneity rather than to chance. I2 values of 25%, 50%, 
and 75% may be considered as indicators of low, moder-
ate, and high heterogeneity, although this has been shown 
to depend on the size and number of trials included.40 In 
instances where significant heterogeneity might be found, 
we planned to conduct sensitivity analyses by removing 
studies, such as those with estimated mean values or those 
of lower methodological quality, in order to determine 
factors related to the heterogeneity and the effect on the 
pooled outcome.
Description of studies
Seven trials,12,13,28–30,32,41 conducted in 3 countries and 
  published in peer-reviewed journals between 2001 and 
2006, met the criteria for inclusion in this review. The total 
number of patients was 1,213; 651 were randomly allocated 
to the PMLR group. All studies employed a holmium:YAG 
laser in their respective intervention groups. Catheter 
systems used to deliver laser energy varied, including the 
ECLIPSE,29,41 the Coaxial Cardiogenesis System,13,30 the 
Axcis PMLR,12,32 and the Biosense direct myocardial revas-
cularization   system.28 The number of laser channels formed 
ranged from 8–35 per patient, depending on location and 
extensiveness of ischemic territory, proximity to cardiac 
structures, and maneuverability of the catheter. Descrip-
tions of the operative protocols including femoral arterial 
access, anticoagulation regimen, and sedation were available 
and similar across 6 of the 7 trials. Techniques used to map 
ischemic territories were described in 6 trials and included 
fluoroscopy and biplane ventriculography and coronary 
angiography in   orthogonal views,12,13,28–30,32,41 left ventricular 
  electromechanical   mapping, and single-photon-emission 
computed tomography (SPECT).28 Across trials, no changes 
were made to participants’ maximally-tolerated antianginal 
therapy in PMLR and control groups.
The characteristics of each trial included are presented in 
Table 1. Sample sizes ranged from 68–330, and all patients 
had CCS Class III–IV angina. One trial included patients 
with a single chronic total occlusion (CTO) and failed 
PCI.41 All trials compared sociodemographic and baseline 
measures between groups; no significant differences were 
found (level of detail varied) with the exception of one trial 
wherein a higher proportion of patients with hyperlipidemia, 
family history of CAD, previous cardiac interventions, and 
a higher median Seattle Angina Questionnaire (SAQ) score 
was found in the control group.12 All trials excluded patients Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of included trials
Study Gray et al 200330
Design RCT
Relevant outcomes, definitions Angina severity, exercise duration, QoL,
Sample size, participant characteristics, setting, country N = 73 (M-70/F-3), RFA patients, CCS class iii–iV, MMT, unsuitable 
for revascularization single UK center, 21 of this sample were also 
analyzed in Oesterle et al, 2000
Measurement occasions, outcome measures, reliability and validity Change in exercise duration, CCS, McGill pain score and SAQ at 
3, 6, 12 mths from baseline, (reliable and valid tools) change in LVeF 
from baseline to 3 mths as assessed on echocardiograph
intervention PMLR plus MMT compared to MMT
Notes Coaxial Cardiogenesis™ PMLR laser system
Study Leon et al 200528 DIRECT Trial
Design RCT
Relevant outcomes, definitions exercise tolerance, angina frequency, QoL, morbidity, mortality, 
myocardial perfusion
Sample size, participant characteristics, setting, country N = 298, (m-229/f-69), RFA patients, CCS class iii–iV, MMT, 
unsuitable for revascularization, 14 US Centers
Measurement occasions, outcome measures, reliability and validity Change in exercise duration from baseline to 6 mths using modified 
Bruce protocol, MACe at 1, 6, 12 mths, procedural adverse events 
at 30 d, change in CCS class from baseline to 6 and 12 mths, SF-12, 
SAQ from baseline to 6 and 12 mths, change in radionuclide perfusion 
scores from baseline to 6 mths
intervention Three arm trial comparing low-dose laser vs high-dose laser  
vs medical management
Notes Holmium:YAG laser with Biosense DMR ™ catheter
Study McNab et al 200632 SPiRiT Trial
Design RCT
Relevant outcomes, definitions exercise tolerance, angina severity, QoL, adverse events, myocardial 
perfusion
Sample size, participant characteristics, setting, country N = 69 (M-60/F-8), RFA patients, CCS class iii–iV, MMT, unsuitable 
for revascularization, UK tertiary referral center
Measurement occasions, outcome measures, reliability and validity Change in exercise treadmill time using modified Bruce protocol, 
CCS class, SF-36, SAQ, and euroqol from baseline at 3 and 12 mths 
procedural and disease-related adverse events documented reliability 
and validity of tools
intervention PMLR compared to intermittent spinal cord stimulation
Notes Axcis PTMR™ Holmium:YAG laser
Study Oesterle et al 200012 PACIFIC Trial
Design RCT
Relevant outcomes, definitions exercise duration, angina severity, survival, death, Mi, hospitalization
Sample size, participant characteristics, setting, country N = 221 (M-190/F-31), RFA patients, CCS class iii–iV, MMT, 
unsuitable for revascularization, 12 US and 1 UK centers
Measurement occasions, outcome measures, reliability and validity Change in exercise duration, CCS and SAQ at 3, 6, 12 mths from 
baseline (reliable and valid tools)
intervention PMLR plus MMT compared to MMT
Notes Axcis PTMR™ Holmium:YAG laser system, 24 patients received 
revascularization procedures during the one year follow-up, analysis 
was done by iTT and also excluding this group
Study Salem et al 200413 Belief Trial
Design RCT
Relevant outcomes, definitions exercise tolerance, angina severity, QοL
Sample size, participant characteristics, setting, country N = 82 (M-75/F-7), RFA patients, CCS class iii–iV, MMT, unsuitable 
for revascularization, 2 Norwegian centers
Measurement occasions, outcome measures, reliability and validity Change in CCS, SAQ, medication usage, from baseline to 6 and  
12 mths, chronotropic assessment exercise protocol used to assess 
change in exercise time, oxygen uptake, and respiratory exchange 
ratio from baseline to 12 mths
(Continued)Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 1 (Continued)
Study Salem et al 200413 Belief Trial
intervention PMLR plus MMT vs MMT
Notes Coaxial Cardiogenesis™ Holmium:YAG system, LVeF reported 
unchanged but no description of instrument used, blinding of all 
personnel, participants and outcome assessors for 12 mths
Study Stone et al 200241
Design RCT
Relevant outcomes, definitions Adverse events, 6 month cumulative MACe
Sample size, participant characteristics, setting, country N = 141 (M-112/F-29), RFA patients, CCS class iii–iV, MMT, 
unsuitable for revascularization, 17 US centers
Measurement occasions, outcome measures, reliability and validity Change in exercise duration with Bruce protocol and CCS from 
baseline to 6 and 12 mths, difference in MACe between groups
intervention PMLR vs MMT
Notes enrolled after failed attempt at PCi, no description of randomization 
process, only procedure room staff aware of group allocation, 
eclipse™ Holmium:YAG system
Study Whitlow et al 200329
Design RCT
Relevant outcomes, definitions exercise duration, angina severity, QoL
Sample size, participant characteristics, setting, country N = 330 (M-245/F-85) RFA patients, CCS class iii–iV,MMT, unsuitable 
for revascularization
Measurement occasions, outcome measures, reliability and validity Change in exercise tolerance (Naughton protocol) and from baseline 
to 12 mths, change in CCS, DASi from baseline to 6 and 12 mths
intervention PMLR plus MMT vs MMT
Notes eclipse™ Holmium:YAG laser system, no patient blinding
Abbreviations: CCS, Canadian Cardiovascular Society; d, days; DASi, Duke Activity Status index; LVeF, left ventricular ejection fraction; MACe, major adverse cardiovascular 
event;  Mi,  myocardial  infarction;  MMT,  maximum  medical  therapy;  mths,  months;  PCi,  percutaneous  coronary  intervention;  PMLR,  percutaneous  myocardial  laser 
revascularization; QoL, quality of life; RFA, refractory angina; SF-12, Medical Outcome Study: General Health Survey; SF-36, Medical Outcomes Study: 36 item Short Form; 
SAQ, Seattle Angina Questionnaire; YAG, yttrium-aluminum-garnet.
with a recent MI, aortic stenosis, mechanical aortic valve, 
  peripheral vascular disease precluding the insertion of a 
9 French   arterial access catheter, diminished left ventricular 
(LV) function (ejection fraction ,25%–30%), and myocar-
dial wall thickness less than 8–9 mm in the laser-targeted 
region(s). Additional exclusion criteria in some trials included 
clinically significant ventricular arrhythmias,12,13,30,41 left ven-
tricular thrombus,12,13,28–30,41 pacemakers and defibrillators,32 
and chronic atrial fibrillation.28
Relevant outcome measures in the trials reviewed are 
presented in Table 2. All trials examined the impact of PMLR 
on angina pain symptoms and exercise tolerance. The CCS 
classification system was used to measure angina pain across 
trials; one trial30 also used the McGill Pain Questionnaire. 
Measures of exercise performance included the modified 
Bruce protocol,12,28,30,32,41 the Naughton protocol,29 and tread-
mill or bicycle ergometry.13 Six trials reported HRQL out-
comes using various measures including the SAQ,12,13,28,30,32 
the Short Form (SF)-12,28 the Short Form (SF)-36,32 the 
EuroQoL,32 and the Duke Activity Status Index (DASI).29 
Adverse events and mortality   during follow-up were reported 
across trials; means to capture these data included cumulative 
major adverse cardiac events (MACE) including death, MI 
and revascularization,12,28,41 freedom from MACE,12,13,28,29 
event-free survival,13 periprocedural28–30,12 and vascular12,32 
complications, hospital admissions,12,13,30 increase in anti-
anginal medications,12,13,30 and medical complications, 
including cerebral vascular accident (CVA), transient isch-
emic attack (TIA), heart failure, and arrhythmias.12,30 Length 
of follow-up period for data collection ranged from 3–12 
months, varying by outcome and rate of attrition.
Risk of bias in included studies
Details of our risk of bias assessment are provided in Figures 
1a and 1b. One trial by Gray et al30 was excluded from meta-
analysis due to a number of methodological shortcomings. 
First, clinical results were presented for 73 patients using trial 
procedures from the PACIFIC trial.12 While these procedures 
included a process of randomization, no a priori sample size 
calculation or stopping rules were stated. Second, analyses 
were conducted on an ongoing basis and recruitment was 
stopped when sufficient evidence was available from both 
this and the PACIFIC trial to make decisions about the con-
tinued use of PMLR. Finally, 21 participants in Gray et al’s Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 2 Outcomes relevant to this review reported by authors
Trial  Angina pain symptoms  Exercise duration  HRQL Adverse events
Gray et al 200330  CCS class, 
McGill pain questionnaire
Modified Bruce protocol  SAQ Hospital admissions  
Cerebral vascular accident 
Transient ischemic attack 
Other periprocedural and vascular  
complications 
Hospital admissions 
Arrythmias 
Heart failure 
increase in antianginal medication
Leon et al 200528  CCS class Modified Bruce protocol  SAQ 
SF-12
MACe 
LV perforation 
Stroke 
Other periprocedural complications
McNab et al 200632 CCS class  Modified Bruce protocol euroQOL 
SAQ 
SF-36
Vascular complications 
All-cause mortality
Oesterle et al 200012 CCS class  Modified Bruce protocol  SAQ  MACe 
Cerebral vascular accident  
Transient ischemic attack 
Other periprocedural and vascular 
complications  
Hospital admissions 
Arrythmias 
Heart failure 
increase in antianginal medication
Salem et al 200413  CCS class  Bicycle ergometry  SAQ  LV Function 
event-free survival 
Hospital admissions 
MACe 
increase in antianginal medication
Stone et al 200241  CCS class Modified Bruce protocol MACe 
Periprocedural complications 
whitlow et al 200329  CCS class  Naughton protocol  Duke activity  
status index 
Periprocedural complications 
MACe 
trial were also participants in the PACIFIC trial; and since 
outcome data were not separated by trial, this precluded their 
use for meta-analysis.
The methodological quality of the remaining six trials 
ranged from moderate to high. We considered 4 to be of 
high quality12,13,28,32 and 2 of moderate quality.29,41 A number 
of reports did not adequately describe the randomization 
process (sequence generation and allocation concealment) 
but none used methods that were of obvious poor quality. 
Blinding of outcome assessors was clearly reported in 5 
of the 6 trials (83%). Blinding of the patients and of the 
personnel caring for them occurred in 4 (66%) and 3 (50%) 
of the trials respectively. A sham procedure was used in 3 
trials (50%). Loss-to-follow-up rates ranged from 0%–12% 
across the 4 trials of high methodological quality.12,13,28,32 
Of the remaining two trials, the loss-to-follow-up rate 
was 45% in one41 and presumably 0% in the other29 as 
no losses-to-follow-up were reported. Five trials12,13,28,29,32 
reported on all prespecified outcomes at all time points. In 
the remaining trial by Stone et al41 all prespecified outcomes 
were reported at 3 and 6 months, but prespecified 12-month 
data were not included. This trial was also excluded from 
our meta-analysis because of inadequate reporting and the 
high loss-to-follow-up rate (45%).
Effects of interventions
The  impact  of  PMLR  was  evaluated  at  12  months 
  post-intervention across outcomes measured. The DIRECT 
trial28 included three arms: a sham procedure, low-dose 
(10–15 pulses) and high-dose (20–25 pulses) laser treatment 
groups, respectively. Since this trial found no significant 
differences in the effects of high- and low-dose laser treat-
ment we therefore decided a priori to conduct our primary 
meta-analysis using data from the low-dose laser group in 
order to be conservative. As a form of sensitivity analysis, 
we conducted secondary meta-analyses for each outcome Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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B
Figure 1 Risk of bias assessment of included studies expressed as A) yes/no/unclear, and B) percentage.
using data from the high-dose group in order to identify any 
possible changes in the magnitude of our pooled estimates 
of effect.
With respect to our primary meta-analysis, the PACIFIC 
trial12 was a significant source of heterogeneity (ie, I2 . 50%) 
across all outcomes apart from mortality. This was likely due to 
the fact that summary data in the PACIFIC trial were expressed 
as medians and interquartile ranges (IQR), requiring estimation 
of means and standard deviations (SD). (Our original inclusion 
of PACIFIC trial data did not result in any significant shift 
in the direction of magnitude of pooled estimates of effect.) 
Details of outcomes pertaining to CCS class, HRQL, and 
exercise duration are therefore based on sensitivity analyses 
which ultimately excluded PACIFIC trial data.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Primary analyses
CCS class
Data pertaining to changes in CCS class were available 
in three trials.13,28,29 We examined the impact of PMLR 
on change in CCS class of two categories or more, as this 
approach was standard across included trials. Two of the 
three trials showed a significant reduction in at least 2 angina 
classes; ORs ranged from 1.32 to 2.74, with a pooled OR of 
2.13 (95% CI 1.22 to 3.73) (Figure 2), demonstrating an over-
all significant impact of PMLR on CCS class (P = 0.008).
Health-related quality of life
Extractable data were available from two trials,13,28 that exam-
ined the impact of PMLR on self-reported HRQL with the 
disease-specific SAQ. The SAQ quantifies five clinically 
relevant domains of disease-specific HRQL including: angina 
frequency, angina stability, disease perception, physical limi-
tation, and treatment satisfaction; no overall functional status 
summary score is derived.42 As seen in Figures 3, 4, and 5 
results of our meta-analyses showed significant improvements 
in angina frequency [SMD = 0.29, 95% CI, 0.05 to 0.52, P = 
0.02], disease perception [SMD = 0.37, 95% CI, 0.14 to 0.61. P 
= 0.002], and physical limitation [SMD = 0.29, 95% CI = 0.05 to 
0.53, P = 0.02]. No significant improvements in angina stability 
or treatment satisfaction were found (Figures 6 and 7).
exercise performance
Exercise performance, measured as exercise duration in sec-
onds, was examined using data from three trials.13,28,29 Two 
trials showed no significant increase in exercise duration, 
with SMDs of –0.04 and 0.15 respectively. An overall pooled 
SMD across trials of 0.23, 95% (CI = –0.06 to 0.53), found no 
significant difference between treatment and control groups 
regarding exercise duration (P = 0.12) (Figure 8).
Mortality
Mortality and adverse event-related data were   available from 4 
trials (including the PACIFIC trial).12,13,28,29 Event-free survival 
data were reported via Kaplan-Meier curves or proportions; 
reporting of mortality data in combination with adverse out-
comes varied across trials precluding a detailed approach to 
a) patient survival versus the occurrence of adverse events, 
and b) disease-specific mortality. We therefore examined 
all-cause mortality using absolute number of deaths reported. 
No trials showed significant differences between treatment 
and control groups, with ORs ranging from 0.33 to 3.05. 
PMLR was not found to have a significant overall impact on 
all-cause mortality: pooled OR, 1.34 (95% CI 0.44 to 4.03, 
P = 0.61); our test for heterogeneity was not significant (Chi2 
: 2.66, P = 0.45, I2 = 0%) (Figure 9).
Secondary analyses
As a form of sensitivity analysis, meta-analyses were 
repeated using data from the DIRECT Trial28 high-dose laser 
group as opposed to the low-dose laser group. The results 
of these secondary analyses are presented in Table 3. When 
the high-dose laser group data were used, no significant 
differences between treatment and control groups, across 
outcomes, were found.
Discussion
In this review we have appraised the summarized 12-month 
outcomes of 5 trials, conducted in 3 countries, of PMLR 
versus maximal medical therapy for RFA management; data 
from 2 of the original 7 trials reviewed were excluded due to 
poor methodological quality. The search strategy to identify 
these trials was comprehensive for PMLR-specific interven-
tions with a restriction of publication in the English language. 
All trials reviewed included patients with refractory angina 
characterized by CCS class III or IV symptoms no longer 
amenable to conventional revascularization procedures and 
treated with maximally-tolerated antianginal therapy. The 
methodological quality of the 5 trials ranged from moderate 
to high, with 5 trials blinding outcome assessors, 4 trials 
blinding participants, and 3 trials blinding PMLR operators 
and other clinicians involved.
With respect to our primary analyses, PMLR was found 
to significantly reduce angina by at least two CCS classes 
and significantly improve three dimensions of self-reported 
HRQL measured via the SAQ including: angina stability, 
angina-induced physical limitations, and disease perception. 
Pooled SMDs for these SAQ subscales ranged from 0.29 to 
0.37 suggesting a small difference36,37 in the positive impact 
of PMLR plus maximal medical therapy (ie, treatment) 
versus maximal medical therapy alone (ie, control). Taken 
together, despite the small SMDs, these results, with the 
significant improvements found in CCS class, are encourag-
ing, considering the high levels of perceived psychological 
burden and related disability known to be associated with 
unrelieved CCS Class III–IV angina symptoms.3–8 Our 
results are consistent with findings of a recent Cochrane 
Review of TMLR14 where those who underwent TMLR 
experienced significant reductions in CCS angina class 
and significant improvement in perceived physical limita-
tion as compared to controls receiving optimal antianginal 
medical therapy.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 2 Comparison of PMLR versus maximal medical therapy, outcome CCS Class.
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Figure 3 Comparison of PMLR versus maximal medical therapy, outcome angina frequency (AF).
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Figure 4 Comparison of PMLR versus maximal medical therapy, outcome disease perception (DP).
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Figure 5 Comparison of PMLR versus maximal medical therapy, outcome physical limitation (PL).
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Figure 6 Comparison of PMLR versus maximal medical therapy, outcome angina severity (AS).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 7 Comparison of PMLR versus maximal medical therapy, outcome treatment satisfaction (TS).
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Figure 8 Comparison of PMLR versus maximal medical therapy, outcome exercise duration.
Notably, neither PMLR nor TMLR14 has been found to 
significantly improve SAQ angina frequency or treatment 
satisfaction scores. A plausible explanation for discordance 
between observed improvements in CCS class and lack of 
improvements in SAQ-angina frequency scores may lie with 
the psychometric properties of the SAQ angina frequency 
subscale. One of two items comprising this subscale asks 
patients to recall how many times in the past 4 weeks they 
have had to take sublingual nitroglycerin for chest pain. This 
item would be irrelevant to most patients included in these 
trials who are on maximally-tolerated oral or transcutaneous 
long-acting nitrate preparations (with nitrate-free intervals 
to minimize tolerance). A focus on short-acting sublingual 
nitroglycerine preparations may therefore render the angina 
frequency subscale insensitive to more global symptom-
related improvements, such as those captured by the CCS 
scale, for RFA patients following laser therapy.
Lack of significant improvements in SAQ treatment 
satisfaction scores may also be a measurement issue. The 
treatment satisfaction subscale comprises 3 items, one of 
which is oriented toward patient satisfaction with physician-
related care.42 At the individual trial level, care may have 
been delivered by more than one physician and/or provided 
by other health care professionals during the course of study 
follow-up. Such variations would therefore introduce loss of 
precision in the measurement of potential improvements in 
patient-physician rapport following intervention.
We found that PMLR did not significantly improve exercise 
performance as measured by exercise duration in seconds. 
However, extractable data were combined from three trials, 
each with different approaches to measurement including 
the modified Bruce protocol,28 the Naughton protocol,29 and 
treadmill or bicycle ergometry.13 Inconsistency in measurement 
across trials may therefore have been a contributing factor, sug-
gesting a need for caution in the interpretation of this finding. 
Interestingly, Brione et al14 also found that divergent approaches 
to measuring exercise performance, across primary trials, were 
problematic in their review of TMLR, with negative results.
With respect to all-cause mortality, our pooling of avail-
able data from 4 trials showed that PMLR did not have a sig-
nificant overall impact. This finding is notable because PMLR 
yields comparable symptom relief to TMLR, yet TMLR was 
found by Brione et al14 to be associated with significant risk 
of early (30-day) postoperative mortality. Moreover, robust 
methods across trials included in this review such as blind-
ing of participants, operators, and outcome assessors, and 
the use of sham procedures suggest that the placebo effect 
is an unlikely explanation for observed reductions in angina 
following PMLR. In contrast, Brione et al14 attributed a high 
risk of bias to observed improvements in angina following 
TMLR due to unmasked outcome assessments across pri-
mary trials.
The available data seem to suggest that PMLR is as effec-
tive as TMLR and that it poses less risk; this is likely because Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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PMLR is less invasive. This cannot however be concluded 
definitively. Lack of detailed reporting on mortality versus 
adverse events in some trials necessitated our examination of 
all-cause mortality. The validity of this endpoint as a proxy 
for the safety of PMLR is uncertain. A more informative 
and acceptable endpoint would be disease-specific mortality, 
requiring consistency and greater precision in the assessment 
of mortality and adverse events in future trials. The incidence 
and severity of periprocedural risks (eg, pericardial effusion 
and hematoma, tamponade, and LV and coronary perforation) 
during PMLR (versus TMLR) should also be examined for 
a more comprehensive assessment of safety.
The inclusion of a third arm in the DIRECT trial28 receiv-
ing high-dose laser therapy required us to rerun our primary 
analyses using data from this high-dose laser group. This was 
done as a form of sensitivity analysis to determine if data 
from the high-dose laser group would exert any change in the 
direction or magnitude of our pooled estimates of effect. Our 
secondary analyses showed that PMLR had no significant 
impact across outcomes, including all-cause mortality. Varia-
tion in scores between the DIRECT trial28 high- and low-dose 
laser groups were found to be similar, suggesting that these 
results were due to a true lack of treatment effect.
This unexpected finding raises the question of appropriate 
laser dose. Across trials, there was a high degree of variability 
in treatment protocol between patients. The number of trans-
mural channels created (per patient) ranged from 8–35, and 
laser pulses per channel ranged from 1–3; the systems used 
to direct laser energy also differed. The contradictory findings 
between our primary and secondary meta-analyses suggest 
an unclear relationship between laser dosage and treatment 
effect. Further work to clarify the underlying mechanisms 
of PMLR may shed light on this relationship and the related 
implications for appropriate laser dosing.
Summary and implications
Refractory angina patients suffer severely impaired HRQL 
and have limited options. This review aimed to assess the 
effects of PMLR versus optimal medical treatment for 
improving pain symptoms, HRQL, and exercise performance 
in patients with RFA. While our primary analyses, based on 
robust trials, showed promising results for improvement in 
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Figure 9 Comparison of PMLR versus maximal medical therapy, outcome all-cause mortality.
Table 3 Secondary analyses: comparison of PMLR versus maximal medical therapy for all outcomes using data from the DiReCT trial 
high-dose group
Variable Pooled standardized  
mean difference
Pooled odds ratio 95% CI for  
difference
P-value
CCS class _ 1.95 [0.90, 4.23] 0.09
Self-reported HRQL
SAQ – AF 0.18 _ [–0.20, 0.57] 0.35
SAQ – AS 0.01 _ [–0.23, 0.24] 0.95
SAQ – DP 0.10 _ [–0.25,0.45] 0.57
SAQ – PL 0.01 _ [–0.23, 0.24] 0.95
SAQ – TS -0.005 _ [–0.30, 0.20] 0.72
Exercise duration  0.17 _ [–0.18, 0.53] 0.97
All-cause mortality  _ 1.34 [0.44, 4.03] 0.61
Abbreviations: AF, angina frequency; AS, angina stability; CCS, Canadian Cardiovascular Society; DP, disease perception; HRQL, health-related quality of life; PL, physical 
limitation; SAQ, Seattle Angina Questionnaire; TS, treatment satisfaction.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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CCS angina class and aspects of HRQL, key questions about 
PMLR remain unanswered. Our data suggest that PMLR is a 
safe treatment option. However, future work should take a more 
detailed approach to a) patient survival versus the occurrence 
of adverse events, and b) disease-specific mortality in order 
to make more definitive conclusions about safety. Clarity is 
also needed regarding the underlying mechanisms of PMLR 
in order to gain a better understanding of the relationship 
between laser dose and the observed benefits of treatment for 
RFA patients.
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